December 7, 2020
Immunicum’s ilixadencel for tumors get’s FDA’s fast track
Immunicum AB has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the Company’s lead…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
December 7, 2020
Relief, NeuroRx to test aviptadil for treating respiratory failure in Covid-19 patients
Relief Therapeutics and NeuroRx have met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration (FDA) in the ongoing phase 2b/3 trial of RLF-100 (aviptadil) for treating Respiratory Failure in patients with Critical COVID-19.
December 3, 2020
Understanding the role of inflammation in COVID-19 patients: a little is good, too much might kill you
COVID-19 is the medical emergency of the century. Since the pandemic began in December 2019, the new coronavirus, termed SARS-CoV-2 has caused havoc in almost every country, with more than 40 million proven cases of the disease termed COVID-19, including one million deaths.
December 2, 2020
UK the world’s first to approve Pfizer/BioNTech covid-19 vaccine
The UK has approved Pfizer’s COVID-19 vaccine on Wednesday, becoming the first country in the world to do so, going ahead of the United States and the EU countries, who expect to bring the decisions on authorization in December.
December 2, 2020
BD invests $1.2 billion over 4 years
BD (Becton, Dickinson and Company) plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six global manufacturing locations and add a new manufacturing facility in Europe.
November 30, 2020
EC Approves Dupixent as the first biologic medicine for children (6-11) with severe atopic dermatitis
Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) has extended the marketing authorization for Dupixent (dupilumab) in the European Union (EU) to include children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients.
November 30, 2020
Carragelose to be tested in preventing COVID-19 infections
The Swansea University Medical School plans a clinical trial with Iota-/kappa-carrageenan nasal spray as a COVID-19 Prophylaxis for Healthcare Professionals (ICE-COVID), to test Marinomed Carragelose nasal and throat spray in reducing the rate, severity, and duration of COVID-19 infections.
November 19, 2020
F4 Pharma: treatment for the most severely affected patients clinical trial with FX06 starts in France
F4 Pharma, a clinical-stage biopharmaceutical company developing FX06, an anti-inflammatory therapeutic that has shown to improve vascular integrity, has included the first patient with severe COVID-19 in a study named “FX-COVID”, to confirm the efficacy and safety of FX06 in hospitalized patients receiving mechanical ventilation.
November 18, 2020
Pfizer’s, Biontech’s Covid-19 vaccine candidate meets endpints in P3 trial
Pfizer’s and Biontech’s vaccine candidate for COVID-19 has met all the study’s primary efficacy endpoints.
November 9, 2020
Pfizer says its Covid-19 vaccine 90% effective
Pfizer says its vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis